Rhythm Biosciences (ASX:RHY) said that its Genetype business recorded its first commercial sales under the company's ownership, according to a Wednesday Australian bourse filing.
The company said it is forecasting an "attractive" sales growth profile for Genetype products over the foreseeable future, driven by potential enterprise customers and support from influential key opinion leaders, among other factors.